Latus Bio Taps Veteran Dealmaker Mancilla for Clinical-Stage Push

PHILADELPHIA, PA – June 16, 2026 – In the high-stakes world of biotechnology, executive appointments are more than just personnel changes; they are strategic signals. Latus Bio, a company engineering gene therapies at scale, sent a clear one today with the appointment of Bethany Mancilla as its new Chief Business Officer. This is not a routine hire. It is a calculated move by a company standing at the precipice of clinical validation, arming itself with a proven dealmaker precisely when it needs one most.

Ms. Mancilla joins Latus from a string of high-profile roles, bringing a formidable resume in corporate development that reads like a tour of biotech’s most dynamic sectors. Her appointment comes as Latus prepares to transition from a promising preclinical entity into a clinical-stage powerhouse, a journey fraught with financial and strategic challenges. For Latus, Mancilla isn't just a new CBO; she's the architect intended to build the commercial and strategic superstructure upon the company's scientific foundation.

A Strategic Inflection Point

The timing of this appointment is critical. Latus is not merely talking about potential; it is actively moving its assets toward human trials. The company is at what CEO P. Peter Ghoroghchian, M.D., Ph.D., calls a “defining moment.” This is no overstatement. Latus is preparing to submit an Investigational New Drug (IND) application for its lead candidate, LTS-201 for Huntington’s disease, in the third quarter of this year. Simultaneously, its program for CLN2 disease, LTS-101, has already received IND clearance and is set to begin a first-in-human trial, also in Q3 2026.

This two-pronged clinical advance validates the “inflection point” narrative. It also explains the recent infusion of a hefty $97 million in Series A financing, announced last month. That capital, secured in what one investor called a “highly selective capital environment for gene therapy,” provides the runway. Mancilla’s job will be to build the fleet. Her mandate is clear: leverage the company’s burgeoning clinical data to forge the partnerships that will define its future.

“Bethany has spent her career translating differentiated science into high-value transactions,” Ghoroghchian noted in the official announcement. “Her leadership will be integral as we advance our strategy and pursue partnerships that extend the reach of our programs and platform for patients with high unmet needs.” The message is unmistakable: with the science de-risked to a clinical entry point, the focus now pivots to strategic execution and value creation.

The Dealmaker and The Pipeline

To understand the impact Mancilla is expected to have, one need only look at her track record. Most recently at Capsida Biotherapeutics, she was instrumental in securing over $250 million in non-dilutive funding—a figure that speaks volumes about her ability to structure deals that fuel research without handing over the company store. Her tenures at Amgen, where she served as Vice President of Business Development, and Kite Pharma place her at the center of some of the industry’s most significant M&A and licensing activities over the past decade.

Her experience at Micromet is particularly telling; she forged the strategic partnership that ultimately led to its acquisition by Amgen. This is the kind of long-range strategic vision Latus is betting on. As a company with a platform technology, its future value lies not just in its own pipeline but in its ability to become an essential partner for larger pharmaceutical players looking to enter the gene therapy space.

“Latus is at a true inflection point as it transitions into a clinical-stage company,” Ms. Mancilla stated. Her commentary focuses squarely on the assets, highlighting LTS-201’s “fundamentally differentiated approach to Huntington’s disease.” This shows she is not just a financier but a strategist who understands the science she will be selling.

Targeting Huntington's at its Root

Huntington's disease represents a formidable challenge and a significant market opportunity. With no disease-modifying therapies currently approved, the unmet need is profound. Latus Bio’s LTS-201 aims to carve out a unique position in a competitive field by not just treating symptoms, but by targeting a root cause of disease progression: somatic instability.

The therapy is designed to reduce the expression of a protein called MSH3, which is responsible for the expansion of the toxic CAG repeats in the Huntingtin gene that drive the disease. By silencing MSH3 in key brain regions, Latus hopes to slow or even halt the relentless neurodegeneration. This specific mechanism is what the company refers to as its “fundamentally differentiated approach.”

While other companies are exploring gene therapy for Huntington’s, many focus on directly silencing the Huntingtin gene itself. Latus’s strategy of targeting the instability engine is a novel angle that, if successful, could offer a powerful new therapeutic paradigm. Mancilla’s deep experience in CNS disorders will be crucial in communicating this scientific nuance to potential partners and navigating the complex clinical and regulatory path ahead.

Beyond Rare Disease: The Promise of Scalable Gene Therapy

Perhaps the most compelling part of the Latus story is its ambition to scale. The company’s platform is built on discovering novel adeno-associated virus (AAV) capsids—the delivery vehicles for gene therapies—that are more potent and specific. This means they can potentially achieve therapeutic effects at much lower doses.

This is not just a technical detail; it is the key to unlocking the future of the field. Lower doses mean improved safety, reduced manufacturing costs, and the potential to treat not just ultra-rare conditions but larger patient populations. In her statement, Mancilla pointed to this, noting that “Latus’ platform is built to scale precision gene therapy for larger patient populations.”

This is where her appointment becomes truly transformative. Her role will be to monetize this platform, identifying “fast follow-programs and novel capsid opportunities” and structuring deals that leverage the technology across a range of diseases. With her at the business development helm, Latus Bio is signaling that it aims to be more than just a Huntington’s company; it aims to be a central player in the industrialization of gene therapy itself.